Scarica l'app Stockscreener
2.17
0.93%
0.02
Dopo l'orario di chiusura:
2.13
-0.04
-1.84%
Precedente Chiudi:
$2.15
Aprire:
$2.1
Volume 24 ore:
57,926
Relative Volume:
0.36
Capitalizzazione di mercato:
$161.09M
Reddito:
-
Utile/perdita netta:
$-2.95M
Rapporto P/E:
-53.98
EPS:
-0.0402
Flusso di cassa netto:
-
1 W Prestazione:
-0.46%
1M Prestazione:
-0.91%
6M Prestazione:
-92.77%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.09
$2.19
Intervallo di 1 settimana:
$2.0065
$2.19
Portata 52W:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Nome
Jyong Biotech Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare MENS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.17 | 159.60M | 0 | -2.95M | 0 | -0.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jyong Biotech Ltd Borsa (MENS) Ultime notizie
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZonePCR Divergence - Newser
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
Inside Jyong Biotech's 2025 SEC annual report filing for investors - Stock Titan
What Jyong Biotech (MENS) management focus reveals about priorities (Risk Aversion) 2026-05-11Crowd Sentiment Stocks - Newser
Jyong Biotech Delays Annual 20-F (Yearly Report) - The Globe and Mail
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - The Manila Times
Jyong Biotech Updates Market Access Strategy for Innovative - GlobeNewswire
Short Interest in Jyong Biotech Ltd. (NASDAQ:MENS) Decreases By 43.2% - MarketBeat
CEO-linked entities report 33.34% Jyong Biotech (MENS) stake via trust - Stock Titan
Jyong Biotech (MENS) Management Strategy | Q1 2025: Earnings ReportPre Earnings - Cổng thông tin điện tử tỉnh Lào Cai
Who Backs Jyong Biotech (MENS) Stock (Risk Aversion) 2026-04-20Investment Picks - Cổng thông tin điện tử tỉnh Lào Cai
Ming Tsan Hsu Net Worth (2026) - GuruFocus
Pang Chieh Chi Net Worth (2026) - GuruFocus
Hung Shu Fan Net Worth (2026) - GuruFocus
Feng Lin Hsu Net Worth (2026) - GuruFocus
Fu Feng Kuo Net Worth (2026) - GuruFocus
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Significant Decrease in Short Interest - MarketBeat
Jyong Biotech Ltd. Live Share Prices and Trades. MENS.US Live Streaming Share Prices. - London South East
Jyong Biotech (NASDAQ: MENS) CFO ZHANG WEI files initial Form 3 - Stock Titan
Wei (vivi) Zhang Net Worth (2026) - GuruFocus
MENS Options Volatility — NASDAQ:MENS - TradingView
MENS Options Chain — NASDAQ:MENS - TradingView
MENS News | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech (MENS) CEO Kuo reports 25,349,500-share indirect stake on Form 3 - Stock Titan
Is Jyong Biotech (MENS) Stock Rebounding | Price at $2.47, Up 0.82%Analyst Upgrade Stocks - Newser
MENS PE Ratio & Valuation, Is MENS Overvalued - Intellectia AI
Director of Jyong Biotech (MENS) files Form 3 showing 3,000 common shares - Stock Titan
Director Hsu Feng-Lin reports 3,000 Jyong Biotech (MENS) shares on Form 3 - Stock Titan
Director at Jyong Biotech (MENS) discloses holding 3,000 shares - Stock Titan
Jyong Biotech (MENS) director Fan Hung-Shu files initial Form 3 - Stock Titan
Jyong Biotech (MENS) director files Form 3 with no insider trades - Stock Titan
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 22.7% in March - Defense World
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - The Manila Times
Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS-2 - Bitget
A plant-based prostate drug finished Phase III trials in the U.S. and Taiwan - Stock Titan
Jyong Biotech Ltd PE Ratio (TTM) & PE Ratio (TTM) ChartsMENS - GuruFocus
Chinese firm sues Taiwan’s Jyong Biotech Ltd. in Cayman to enforce ¥152M China judgment - OffshoreAlert
Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest - MarketBeat
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
MENS Earnings History & Surprises | EPS & Revenue Results | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
MENS Should I Buy - Intellectia AI
Jyong Biotech Ltd Azioni (MENS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):